Key result
Oncolytic enteroviruses, including Coxsackieviruses and vaccine strains, represent a promising and potentially safe source for the development of oncolytic agents for cancer therapy.
Enteroviruses, such as Coxsackieviruses, represent a promising source for the development of safe and selective oncolytic agents for cancer therapy.
Enteroviruses merit further oncolytic development; leaves open prospective trials to confirm safety and efficacy in cancer.
Increasing information concerning molecular biology of viruses and virus-cell interactions makes it possible to use viruses as a tool in effort to treat cancer diseases. As a rule, tumor cells are highly sensitive to viruses that may be used in cancer therapy. Therewith, applications of viral oncolysis in treatment of cancer diseases assume maximum possible safety of used viruses for patient and environment. Human enteroviruses are one of the most convenient sources to generate oncolytic viruses. Many of enteroviruses are non-pathogenic for humans or cause mild disease. Progress in genetic engineering permits to develop attenuated enterovirus variants with high safety and selectivity. This review focuses on the main members of Enterovirus genus, such as Coxsackieviruses, and vaccine strains as promising source for development of oncolytic agents, applicable for cancer therapy. It reviews data concerning recently developed and tested oncolytic variants of enteroviruses and discusses perspectives of their application in cancer therapy and problems, concerning their improvement and practical use.
No takes yet. Share an insight, caveat, or question.
Chumakov et al. (2012) conducted a review in Cancer. Oncolytic enteroviruses was evaluated. Oncolytic enteroviruses, including Coxsackieviruses and vaccine strains, represent a promising and potentially safe source for the development of oncolytic agents for cancer therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: